Company news
Lantheus Holdings, Inc. news in 2022
Lantheus Holdings, Inc.'s news releases, calls and decks from 2022, newest first.
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
December 19, 2022
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
December 11, 2022
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
December 5, 2022
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
December 4, 2022
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
November 28, 2022
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
November 27, 2022
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 13, 2022
Lantheus Reports Third Quarter 2022 Financial Results
November 2, 2022
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8: 00 a.m. Eastern Time
October 19, 2022
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
October 16, 2022
GE Healthcare and Lantheus Phase III Clinical Trial Finds [¹⁸F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
September 12, 2022
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
September 12, 2022
Lantheus Reports Second Quarter 2022 Financial Results
August 3, 2022
Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8: 00 a.m. Eastern Time
July 20, 2022
Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer
June 14, 2022
Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer
June 12, 2022
Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer
June 12, 2022
Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
May 25, 2022
Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting
May 15, 2022
Lantheus Hosts Inaugural Investor Day
May 15, 2022
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients
May 12, 2022
Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer
May 10, 2022
Lantheus to Present at the UBS Global Healthcare Conference
May 9, 2022
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
April 28, 2022
Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8: 00 a.m. Eastern Time
April 14, 2022
Lantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical Officer
April 3, 2022
Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development
March 28, 2022
Lantheus Holdings to Present at the Barclays Global Healthcare Conference
March 7, 2022
Lantheus to Host Inaugural Investor Day
March 2, 2022
Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member
February 28, 2022
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Lantheus Receives U.S. FDA Approval of New Manufacturing Facility
February 22, 2022
Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8: 00 a.m. Eastern Time
February 9, 2022
Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting
February 9, 2022
Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer
January 26, 2022
Calls in 2022
Decks in 2022
- Investor Day (May 2022)
Investor day · 105 slides · May 17, 2022